Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment

Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Yang, Dong Joon Kim, Ashok Kumar Choudhury, Vinod Arora, Shiv Kumar Sarin

Clin Mol Hepatol. 2024;30(3):388-405. Published online April 11, 2024

DOI: https://doi.org/10.3350/cmh.2023.0563

View: 1001 Download: 55

Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea

Yu Rim Lee, Min Kyu Kang, Jeong Eun Song, Hyun Jung Kim, Young Oh Kweon, Won Young Tak, Se Young Jang, Jung Gil Park, Changhyeong Lee, Jae Seok Hwang, Byoung Kuk Jang, Jeong Ill Suh, Woo Jin Chung, Byung Seok Kim, Soo Young Park

Clin Mol Hepatol. 2020;26(4):562-576. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0126

View: 6684 Download: 183 Web of Science: 22 Crossref: 23

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy

Jung Gil Park, Soo Young Park

Clin Mol Hepatol. 2015;21(3):242-248. Published online September 30, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.3.242

View: 8270 Download: 85 Web of Science: 5 Crossref: 3

Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy

Jung Gil Park

Clin Mol Hepatol. 2015;21(3):287-294. Published online September 30, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.3.287

View: 8619 Download: 75 Web of Science: 26 Crossref: 28

Viewed By 5505	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5406	MAFLD: How is it different from NAFLD?
Viewed By 5215	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5095	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4727	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Author :

Author index